Publication: Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions
2
Issued Date
2014-01-01
Resource Type
ISSN
11791942
01145916
01145916
Other identifier(s)
2-s2.0-84911389837
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Drug Safety. Vol.37, No.11 (2014), 903-919
Suggested Citation
Muhammad Amin, Naeti Suksomboon Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions. Drug Safety. Vol.37, No.11 (2014), 903-919. doi:10.1007/s40264-014-0223-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/34600
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions
Author(s)
Other Contributor(s)
Abstract
© 2014, Springer International Publishing Switzerland. The incidence of type 2 diabetes mellitus is increasing rapidly, as are the associated co-morbidities. Consequently, it has become necessary for a diabetic patient to take multiple medications at the same time to delay progression of the disease. This can put patients at an increased risk of moderate to severe drug interactions, which may threaten patients’ life or may deteriorate the quality of their life. Hence, managing drug–drug interactions is the cornerstone of anti-diabetic therapy. Most of the clinically important drug–drug interactions of anti-diabetic agents are related to their metabolic pathways, but drugs that compete for renal excretion or impair renal status can also play an important role. In this review, we have examined the clinical implications and underlying mechanisms of drugs that are likely to alter the pharmacologic response of or cause adverse events with antidiabetic drugs, and we have outlined safe and efficacious treatment modalities.